Recursion obtains FDA approval for AI-discovered cancer ...
Recursion's REC-1245, a novel RBM39 degrader for treating biomarker-enriched solid tumours and lymphoma, received FDA IND clearance for Phase 1/2 trials. Targeting over 100,000 patients in the US and EU5, it aims to address treatment-resistant tumours, with trials expected to start in late 2024.
Reference News
Recursion obtains FDA approval for AI-discovered cancer ...
Recursion's REC-1245, a novel RBM39 degrader for treating biomarker-enriched solid tumours and lymphoma, received FDA IND clearance for Phase 1/2 trials. Targeting over 100,000 patients in the US and EU5, it aims to address treatment-resistant tumours, with trials expected to start in late 2024.